Navigation Links
pro in Medical Technology

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

Results of NIH-sponsored Clinical Trial to be Presented at Retrovirus Conference LEXINGTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating wome...

Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000

9,395 Women Enrolled in Trial Sponsored by Medical Research Council LEXINGTON, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced today the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candi...

ACORN Showcases Oncology CRO, EDC, PRO and Data Warehouse at 44th Annual DIA Meeting

MEMPHIS, Tenn., June 19 /PRNewswire/ -- Accelerated Community Oncology Research Network(TM) (ACORN) will be showcasing its oncology-focused CRO and research network; Guardian EDC(TM); PACE(TM) PRO System; and proprietary oncology-focused data warehouse at the 44th Annual DIA Meeting, June 22-2...

Indevus Pharmaceuticals Provides Update on PRO 2000 Program

LEXINGTON, Mass., Feb. 15 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced today that they have been advised by the United Kingdom's Medical Research Council (MRC) that after review of data from the Phase III clinical trial of PRO 2000, the Company's candidate...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...ness strategy and as a result reported $669,000 of pro forma net income for the quarter ended June 30, 20...over the same period in 2008. Isis also reported a pro forma net operating loss of $1.3 million for the second quarter compared to pro forma net operating income of $4.6 million for the...

GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas

... Amplified Maxertion N.O. is part of a comprehensive line of eight new advanced muscle performance and sports nutrition products from GNC. The entire pro Performance(R) AMP line was developed through rigorous clinical research and is designed to suit the needs of a wide range of dedicated athletes, from...

invivodata Certified to Deliver EXACT in COPD Trials

...data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of pro data in a regulated environment. invivodata's solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in del...

MedNet Solutions Certified to Score SF-12v2 Health Survey

...orrect survey scores and misinterpreted results. "When it comes to measuring health outcomes, the intake, scoring, and reporting of unimpeachable pro data is crucial to QualityMetric and our clients. Toward this end, we developed the QM Certified Scoring Partner program to recognize industry leaders...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...al partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, an...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

...ticipate in low-impact activities that increased their quality of life. The researchers recommend pre-surgical counseling to set expectations. pro Athletes and Knee Surgeries ( http://www3.aaos.org/education/anmeet/anmt2009/poster/poster.cfm?Pevent=P406 ) Unlike Meniscectomy...

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering

...artnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome...

BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease

...e (PRO) questionnaire, which will measure several domains of patients' sexual quality of life, over a 36 week period. The four domains measured by the pro are penile pain, Peyronie's disease bother, intercourse discomfort and intercourse constraint. To qualify for the study, patients must be able to ma...

New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study

...ous formulations) and postoperative ileus (intravenous formulation). In the area of HIV infection, the Company is developing the viral-entry inhibitor pro 140, a humanized monoclonal antibody targeting the HIV entry co-receptor CCR5, which has completed phase 1b clinical studies with positive results. In...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

...artnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly, and a biodegradable urete...

Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests

...9,000 people worldwide and operates in 130 countries. In the fiscal year 2007 (Sept. 30), Siemens Healthcare reported sales of euro 9.85 billion (on a pro forma basis including Dade Behring roughly euro 11 billion), orders of euro 10.27 billion, and group profit of euro 1.32 billion. Further information ...

The Yolanda Adams Morning Show and Radio One Gospel Stations Raise More Than $1 Million During National Radiothon Benefiting St. Jude

... nation's largest radio broadcasting companies and the largest radio broadcasting company that primarily targets African-American and urban listeners. pro forma for recently announced transactions, Radio One owns and/or operates 53 radio stations located in 16 urban markets in the United States. Addition...

Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials

...ing for Progenics' clinical development program of pro 140, an investigational CCR5 monoclonal antibody b...ase 3 studies of CCR5 antagonists to date. About pro 140 Progenics announced the start of the phase 2 program for pro 140 in January 2008....

Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing

...9,000 people worldwide and operates in 130 countries. In the fiscal year 2007 (Sept. 30), Siemens Healthcare reported sales of euro 9.85 billion (on a pro forma basis including Dade Behring roughly euro 11 billion), orders of euro 10.27 billion, and group profit of euro 1.32 billion. Further information ...

FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

...g position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutio...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

...artnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forwa...

Keppra XR(TM) Extended-Release Tablets Filed with the FDA

...g position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and through its affiliate. SCHWARZ PHARMA AG (Monheim, Germany) is a member of the U...

UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets

...g position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHW...

Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

...artnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forwa...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

...g position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approx. 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germ...

Lilly and Glenmark Pharmaceuticals Announce License Agreement

...02 per share. Lilly's fourth-quarter and full-year pro forma adjusted earnings per share guidance remain ... - .31 Include pro forma as if the ICOS acquisition was completed ...OSI in-licensing .58 - Include pro forma as if the ICOS acquisition was completed ...

President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its 'Stop Neglected Tropical Disease' Campaign

... Agency's pro Bono Initiative Aims to Mobilize $25 Million to Eliminate Diseases of Poverty Afflicting the Poorest of the Poor EAST RUTHERFORD, N.J., Oct....

Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome

...g position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approximately 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim...

Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease

...g position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approximately 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim...

Indevus Announces Submission of New Drug Application

...partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Excep...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

... partnered or partnerable programs. The most advanced compounds in development include VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Excep...

Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy

...IDS. Patients receiving a single 5.0 mg/kg dose of pro 140 achieved an average maximum decrease of viral ... for two to three weeks after dosing. In addition, pro 140 was generally well tolerated in this phase 1b proof-of-concept study. pro 140 was granted Fast Track status from the U.S. Fo...

Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

...ontgomery, MD, Senior Vice President, Head of Respiratory Therapeutics, Gilead Sciences. "AIR-CF1 is the first Phase III clinical trial in CF to use a pro as its primary endpoint. We appreciate the collaboration with regulatory authorities and with the CF research community in designing this study and we...

Indevus Reports Positive Data From Phase III NEBIDO Trial

...pounds in development include SANCTURA XR(TM), the once-daily formulation of SANCTURA, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Exc...

Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting

...pounds in development include SANCTURA XR(TM), the once-daily formulation of SANCTURA, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward-Looking Statements Exc...

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

...area of HIV infection, the Company is developing the viral-entry inhibitor, pro 140, a humanized monoclonal antibody targeting the HIV co-receptor CCR5. Recently, the Company announced positive results from its phase 1b trial of pro 140 in HIV-infected individuals. In addition, the Company is conducting res...

Urinalysis Analyzers: Large Capabilities in Every Size Device

...ed by Clinitek analyzers in just one minute, and a simple lookup table is provided for the visual reader to obtain the ratio result. The new Multistix pro products generate more reliable results at the trace protein level than competitive products, and provide Protein-to-Creatinine ratio results, which c...

Hemoglobin Testing at the Point of Care

... children and adult patients. ITC, Edison, N.J., manufactures the Hgb pro Professional Hemoglobin Testing System, consisting of a compact, battery-op...l blood on a test strip, which is then inserted in the test device. The Hgb pro is self-calibrating. It includes data storage for the most recent 250 tests...
Other Tags
(Date:7/22/2014)... emerging as a world-famous vacation spot with natural tourism resources, ... island. The Korea Institute of Geoscience and Mineral Resources (KIGAM) ... recent volcanic eruption was evident 5,000 years ago. That is ... lava spewed out of a volcano 5,000 years ago in ... one the whole peninsula. , The research team led by ...
(Date:7/22/2014)... is known about the the genus of planthopper known ... new one was recently discovered in the southern part ... Jaen. A description of it appears in the open-access ... ). , The new species, Conosimus baenai , ... for his contributions to the taxonomy of Iberian Hemiptera. ...
(Date:7/21/2014)... Their scruffy beards weren,t ironic, but there are reasons ... the Ice Age. , According to research from the ... liked living in Greater Cincinnati long before it was ... age. A study led by Brooke Crowley, an assistant ... enjoyed the area so much they likely were year-round ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3
(Date:7/22/2014)... Dr. Dental is excited to announce the ... visitors in mind, one of the main differences from the ... makes navigation very easy. Dr. Dental is renowned for having ... the dentist affordable, convenient and fun, and the new website ... an appointment scheduling system right on the home page where ...
(Date:7/22/2014)... 22, 2014 The 2014 Warrior-Family ... Ronald Reagan Building and International Trade Center in ... Families and Civilian Communities,” will be held from ... 7:30 a.m.) and cohosted by the Military Officers ... Industrial Association (NDIA). USAA is the Executive Sponsor ...
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... Steven Reinberg HealthDay ... Two treatments that break up blood clots deep in the ... death risk. However, one results in a greater risk of ... cost of the other treatment, a new study finds. ... vein thrombosis (DVT) -- is blood-thinning medications and compression stockings. ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
Other Contents